OBiO Technology, a leading contract development and manufacturing organization for cell and gene therapy, is set to present its latest achievements at the upcoming American Society of Gene & Cell Therapy (ASGCT) conference in Maryland, USA. The company will showcase nine posters, including three self-developed patented achievements, four advancements in process optimization, and two cutting-edge technology introductions.
These presentations highlight OBiO Technology’s significant advances in the field of gene therapy, focusing on enhancing vector yield and efficiency, optimizing therapeutic processes, and reducing production costs. By offering innovative and cost-effective production methods, OBiO Technology aims to accelerate the development of clinical projects in gene and cell therapy.
At the ASGCT conference, OBiO Technology experts will demonstrate how their comprehensive viral vector platform can expedite development timelines, mitigate manufacturing risks, and deliver superior performance and product quality at a lower cost. The company is proud to showcase its commitment to relentless innovation and collaborative problem-solving.
Javier Jia Guo, Ph.D., Chief Executive Officer of OBiO Technology, expressed excitement about participating in the ASGCT conference, stating, “We are thrilled to showcase our latest achievements in gene and cell therapy. Our presentations embody our dedication to continuous improvement and technological advancements, as well as our progress in enhancing yield efficiency and streamlining production processes. OBiO Technology remains dedicated to driving the gene and cell therapy industry forward.”
OBiO Technology is a pioneering Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) in the gene and cell therapy field. With state-of-the-art facilities and expertise in vectorology studies, functional genomics, and process development, the company ensures readiness for clinical trials and supports all stages of manufacturing. OBiO Technology’s commitment to enabling gene therapy for better lives is evident in their delivery of high-quality CDMO services worldwide.
As the gene and cell therapy industry continues to advance, OBiO Technology remains at the forefront, continuously improving products and impacting populations worldwide. Their expertise spans various viral vectors, including plasmids, mRNA, AAV, LVV, and Ad vectors, as well as cell therapies like CAR-T, NK, and Treg. Additionally, they are at the forefront of cutting-edge technologies such as inducible viral vector packaging, ultralow endotoxin processes, and tissue-specific AAV variants.
OBiO Technology’s presence at the ASGCT conference underscores their commitment to driving innovation and shaping the future of gene and cell therapy.
In addition to the information provided in the article, it is important to note some current market trends in the gene and cell therapy industry. According to a report by Grand View Research, the global gene therapy market size was valued at $536.13 million in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 31.1% from 2021 to 2028. Factors such as advancements in gene delivery systems, increasing prevalence of genetic disorders, and growing investment in research and development are driving the market growth.
Furthermore, the gene and cell therapy industry has witnessed significant investment and partnerships by pharmaceutical companies and biotech startups. Companies like Novartis, Gilead Sciences, and Pfizer have made substantial investments in the field, indicating the potential for future growth and innovation.
In terms of forecasts, it is expected that the gene and cell therapy market will continue to grow as more therapies receive regulatory approvals and enter the market. The development of gene editing technologies, such as CRISPR-Cas9, also holds great promise for the future of gene therapy.
However, there are also key challenges and controversies associated with gene and cell therapy. One challenge is the high cost of these therapies, which can limit access for patients. Manufacturing complexities and regulatory requirements also pose challenges, as maintaining consistent quality and scalability can be difficult. Additionally, ethical concerns related to the use of genetic engineering in humans and potential long-term side effects of gene therapies are topics of ongoing debate.
Overall, gene and cell therapy offer tremendous potential for addressing unmet medical needs, but they also present challenges that need to be addressed for widespread adoption and accessibility.
Suggested related links:
1. Gene and Cell Therapy Info
2. American Society of Gene & Cell Therapy
3. Grand View Research – Gene Therapy Market Analysis